Recursion Pharmaceuticals (RXRX) Free Cash Flow Growth (3y) (2023 - 2026)
Recursion Pharmaceuticals (RXRX) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 31.42% |
| 10 | Recursion Pharmaceuticals | 1.63 Bn | 967.63 Mn | -6.02 Mn | -1.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.20% |
| Dec 31, 2025 | 1.12% |
| Sep 30, 2025 | -31.77% |
| Jun 30, 2025 | -6.79% |
| Mar 31, 2025 | -56.48% |
| Dec 31, 2024 | -21.16% |
| Sep 30, 2024 | -18.46% |
| Jun 30, 2024 | -9.12% |
| Mar 31, 2024 | -51.30% |
| Dec 31, 2023 | -169.66% |
| Sep 30, 2023 | -53.19% |
| Jun 30, 2023 | -51.22% |
| Mar 31, 2023 | -63.93% |